GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for depression. Its lead product candidate is GH001, an inhalable mebufotenin product candidate currently in Phase 2b clinical trials for treatment-resistant depression and in Phase 2a trials for bipolar II disorder and postpartum depression. The company also has GH002, an intravenous mebufotenin candidate in Phase 1 trials for psychiatric and neurological disorders. GH Research operates through its subsidiary and is dedicated to addressing unmet needs in mental health.

GH Research PLC is listed on the NasdaqGM exchange under the ticker symbol GHRS. Its securities trade in US dollars (USD). The company is headquartered in Dublin, Ireland, but its shares are traded on a US exchange, providing access to global investors.

GH Research PLC operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies, particularly in the area of mental health. Its work involves clinical-stage drug development, with a strong emphasis on mebufotenin-based treatments for depression and related disorders.

GH Research PLC is headquartered in Dublin, Ireland, and was founded in 2018. The company primarily serves the United States market, as indicated by its focus on developing treatments for depression in the US. Its clinical trials are conducted in the US, and it aims to address the needs of patients with treatment-resistant depression, bipolar II disorder, and postpartum depression.

GH Research PLC is a clinical-stage biopharmaceutical company that does not yet have approved products or generate revenue from product sales. Its business model involves advancing its pipeline of mebufotenin-based candidates through clinical trials. The company's lead candidate, GH001, is an inhalable formulation targeting multiple psychiatric indications. GH002, an intravenous candidate, is in early-stage trials. The company likely relies on equity financing, partnerships, or grants to fund its operations until potential regulatory approval and commercialization.